Three hundred recruits were classified as either allergic or nonallergic to inhalant allergens on the basis of history, physical examination, skin testing, and RAST. Forty-nine (16.3%) were classified as allergic as they were affected by oculorhinitis and/or asthma. This diagnosis was compared with results obtained with PRIST and with a new commercially available multi-RAST test for inhalant allergy, Phadiatop (Pharmacia). Sixty subjects (20%), including all 49 allergic subjects, scored positive in the Phadiatop assay (100% sensitivity) while PRIST (cut-off 220 IU/mL) identified only 20/49 allergics (40.8% sensitivity). The correlation between RAST and Phadiatop was excellent. Phadiatop is much more sensitive than PRIST; furthermore, Phadiatop is easier, less expensive, and as reliable as RAST for use in mass screening programs.